Skip to main content
. 2018 Dec 11;91(24):e2211–e2221. doi: 10.1212/WNL.0000000000006640

Figure 3. Reduction in MHDs at each month.

Figure 3

Reduction in migraine headache days (MHDs) at each month was statistically greater in both galcanezumab dose groups compared with placebo. Differences between galcanezumab doses were not significant. LS = least squares; SE = standard error. ***p < 0.001 vs placebo; **p < 0.01 vs placebo.